false000183559700018355972022-06-162022-06-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2022

 

 

PepGen Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-41374	85-3819886
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
245 Main Street
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 781 797-0979

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		PEPG		NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

---

Item 2.02 Results of Operations and Financial Condition.

On June 16, 2022, PepGen Inc. announced its financial results for the quarter ended March 31, 2022 and other business updates. A copy of the press release is furnished as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:

99.1	Press release issued by PepGen Inc. on June 16, 2022
104	Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			PepGen Inc.
Date:	June 16, 2022	By:	/s/ Noel Donnelly
			Noel Donnelly, Chief Financial Officer

 

---

 

 

PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

 

Boston, June 16, 2022 – PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2022.

 

“This has been a year of tremendous growth for PepGen, culminating in our recent transition to a clinical stage company and execution of a successful initial public offering,” stated James McArthur, Ph.D., President and CEO of PepGen. “We are continuing to drive our programs forward, and in April of this year we entered the clinic with PGN-EDO51, our lead program for the treatment of individuals with Duchenne muscular dystrophy (DMD) who are amenable to an exon 51 skipping approach. We look forward to reporting safety, pharmacokinetic and exon skipping data from our Phase 1 healthy normal volunteer study of PGN-EDO51 by the end of 2022 – this will be an important milestone in our efforts to advance this therapy for patients in desperate need of more effective treatment options.”

 

Recent Corporate Highlights

 

Anticipated Upcoming Milestones

---

 

Financial Results for the Three Months Ended March 31, 2022

 

About PepGen

 

PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the ongoing Phase 1 study of PGN-EDO51, the filing of an IND application for PGN-EDODM1, the reporting of non-human primate data for PGN-EDO53 and the nomination of development candidates; and statements about our clinical and pre-clinical programs, product

---

candidates, expected cash runway, achievement of milestones, and corporate and clinical/pre-clinical strategies.

 

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1 trial for EDO51 and pre-clinical studies of other product candidates and obtain required approval before commercialization; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen’s programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent quarterly report on Form 10-Q to be filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

 

Investor Contact
Laurence Watts
Gilmartin Group
Laurence@gilmartinir.com

 

Media Contact
Gwendolyn Schanker
LifeSci Communications
(269) 921-3607
gschanker@lifescicomms.com

 

 

 

 

 

 

 

 

 

 

 

 

 

---

Condensed Consolidated Statements of Operations

(unaudited)

 

		Three Months Ended March 31,
		2022		2021
Operating expenses:
Research and development		$ 10,707		$ 5,530
General and administrative		3,186		1,098
Total operating expenses		$ 13,893		$ 6,628
Operating loss		$ (13,893)		$ (6,628)
Other income (expense)
Interest income		9		—
Other income (expense), net		58		(8)
Total other income (expense), net		67		(8)
Net loss before income tax		$ (13,826)		$ (6,636)
Income tax expense		(4,420)		—
Net loss		$ (18,246)		$ (6,636)
Net loss per share, basic and diluted		$ (18.94)		$ (7.42)
Weighted-average common shares outstanding, basic and diluted		963,588		894,060

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

---

Condensed Consolidated Balance Sheets

(unaudited)

 

		March 31, 2022		December 31, 2021
Assets
Current assets:
Cash and cash equivalents		$ 118,854		$ 132,895
Other receivables		4,574		4,744
Prepaid expenses and other current assets		2,240		2,347
Total current assets		$ 125,668		$ 139,986
Property and equipment, net		2,569		636
Other assets		3,642		3,019
Total assets		$ 131,879		$ 143,641
Liabilities, convertible preferred stock, and stockholders’ deficit
Current liabilities:
Accounts payable		$ 1,888		$ 3,240
Accrued expenses		14,234		7,081
Total current liabilities		16,122		10,321
Preferred stock warrant liability		168		226
Total liabilities		16,290		10,547
Commitments and contingencies
Convertible preferred stock		165,176		165,176
Stockholders’ deficit:
Common Stock		—		—
Additional paid-in capital		2,468		1,653
Accumulated other comprehensive (loss) income		(57)		17
Accumulated deficit		(51,998)		(33,752)
Total stockholders’ deficit		(49,587)		(32,082)
Total liabilities, convertible preferred stock, and stockholders’ deficit		$ 131,879		$ 143,641

 

---